[go: up one dir, main page]

WO2008020180A3 - Methods of increasing the sensitivity of cancer cells to dna damage - Google Patents

Methods of increasing the sensitivity of cancer cells to dna damage Download PDF

Info

Publication number
WO2008020180A3
WO2008020180A3 PCT/GB2007/003062 GB2007003062W WO2008020180A3 WO 2008020180 A3 WO2008020180 A3 WO 2008020180A3 GB 2007003062 W GB2007003062 W GB 2007003062W WO 2008020180 A3 WO2008020180 A3 WO 2008020180A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna damage
methods
sensitivity
increasing
promoting agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/003062
Other languages
French (fr)
Other versions
WO2008020180A2 (en
Inventor
Alan Ashworth
Christopher James Lord
Nicholas Charles Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Kudos Pharmaceuticals Ltd
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Kudos Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital, Kudos Pharmaceuticals Ltd filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of WO2008020180A2 publication Critical patent/WO2008020180A2/en
Publication of WO2008020180A3 publication Critical patent/WO2008020180A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)

Abstract

The present invention relates to the finding that cells which have a kinase-deficient phenotype have increased sensitivity to DNA damage promoting agents, in particular PARP inhibitors. Methods of treating cancers with a kinase-deficient phenotype using DNA damage promoting agents and methods of treating cancers with a combination of DNA damage promoting agents and kinase inhibitors are provided, along with screening methods for identifying new therapeutics for use in combination with DNA damage promoting agents.
PCT/GB2007/003062 2006-08-17 2007-08-10 Methods of increasing the sensitivity of cancer cells to dna damage Ceased WO2008020180A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83870306P 2006-08-17 2006-08-17
US60/838,703 2006-08-17

Publications (2)

Publication Number Publication Date
WO2008020180A2 WO2008020180A2 (en) 2008-02-21
WO2008020180A3 true WO2008020180A3 (en) 2009-01-29

Family

ID=38740360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003062 Ceased WO2008020180A2 (en) 2006-08-17 2007-08-10 Methods of increasing the sensitivity of cancer cells to dna damage

Country Status (1)

Country Link
WO (1) WO2008020180A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008256562A1 (en) * 2007-05-25 2008-12-04 Astrazeneca Ab Combination of CHK and PARP inhibitors for the treatment of cancers
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
JP6925265B2 (en) * 2014-09-16 2021-08-25 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ Discovery of Affinity Reagents and Catalysts by Fiber Optic Array Scanning Technology The present invention was made with national treasury assistance under Contract No. N66601-14-C-4059 awarded by Space and Naval Warfare Systems Command Systems Center Pacific. Government has certain rights with respect to the present invention.
CA3159461A1 (en) 2019-11-25 2021-06-03 Iwao Ojima Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AGUILAR-QUESADA ROCIO ET AL: "Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition", BMC MOLECULAR BIOLOGY, vol. 8, April 2007 (2007-04-01), pages Article No.: 29, XP002498067, ISSN: 1471-2199 *
BOULTON SALLYANNE ET AL: "Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage", CARCINOGENESIS (OXFORD), vol. 20, no. 2, February 1999 (1999-02-01), pages 199 - 203, XP002498069, ISSN: 0143-3334 *
GRAZIANI G ET AL: "PARP-1 inhibition to treat cancer, ischemia, inflammation", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 52, no. 1, 1 July 2005 (2005-07-01), pages 1 - 4, XP004902631, ISSN: 1043-6618 *
MCCABE NUALA ET AL: "Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition", CANCER RESEARCH, vol. 66, no. 16, 15 August 2006 (2006-08-15), pages 8109 - 8115, XP002498068, ISSN: 0008-5472 *
PLUMMER ET AL: "Inhibition of poly(ADP-ribose) polymerase in cancer", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 6, no. 4, 1 August 2006 (2006-08-01), pages 364 - 368, XP005539064, ISSN: 1471-4892 *
SARKARIA JANN N ET AL: "Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine", CANCER RESEARCH, vol. 59, no. 17, 1 September 1999 (1999-09-01), pages 4375 - 4382, XP002498070, ISSN: 0008-5472 *
TURNER NICHOLAS C ET AL: "A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 27, no. 9, May 2008 (2008-05-01), pages 1368 - 1377, XP002498071, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
WO2008020180A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
WO2010030365A3 (en) Thyroid tumors identified
PL2450437T3 (en) Gene defects and mutated ALK kinase in human solid tumors
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2007149476A3 (en) Assays for non-apoptotic cell death and uses thereof
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2007008759A3 (en) Methods for detecting and confirming minimal disease in a cancer patient
WO2010104598A3 (en) Kinase protein binding inhibitors
WO2009054939A8 (en) Cancer classification and methods of use
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2009108931A3 (en) Method of treating cancer
WO2007103146A3 (en) Truncated proteins as cancer markers
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
WO2006010150A3 (en) Housekeeping genes and methods for identifying the same
BRPI0818555A2 (en) Multi-electrode ion meter, and Multi-electrode ion probe
WO2008020180A3 (en) Methods of increasing the sensitivity of cancer cells to dna damage
WO2005080593A3 (en) P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
ZA200804973B (en) Methods for identifying and targeting tumor stem cells based on nuclear morphology
WO2006116016A3 (en) Molecular determinants of egfr kinase inhibitor response in glioblastoma
PT1611890E (en) Methods for assessing and treating cancer
WO2010033986A3 (en) Dna cytosine deaminase inhibitors
WO2006034456A3 (en) Compositions and methods for detecting and treating tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789188

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789188

Country of ref document: EP

Kind code of ref document: A2